BusinessSPR Therapeutics® Secures $25 Million in Series C FinancingBy Nasdaq OMXSep 12, 2017, 12:03 PM UTC
BusinessSPR Therapeutics Promotes Dr. Joseph Boggs to SVP of Research and DevelopmentBy Nasdaq OMXSep 7, 2017, 1:13 PM UTC
BusinessOpioid Concerns and Work Interference Cited as Top Reasons to Delay Knee Replacement SurgeryBy Nasdaq OMXAug 3, 2017, 3:03 PM UTC
